A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing

Journal of Clinical Microbiology

Volumn 53, Issue 6, 2015, Pages 1812-1822

  Valsesia, Giorgia ^a   Roos, Malgorzata ^a   Böttger, Erik C ^a   Hombach, Michael ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; ERTAPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

AMPC CEPHALOSPORINASE POSITIVE ESCHERICHIA COLI; AMPC CEPHALOSPORINASE POSITIVE KLEBSIELLA PNEUMONIAE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BROAD SPECTRUM BETA LACTAMASE POSITIVE ESCHERICHIA COLI; CONTROLLED STUDY; DISK DIFFUSION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE POSITIVE ENTEROBACTER CLOACAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; WILD TYPE; AREA UNDER THE CURVE; BACTERIAL INFECTIONS; BACTERIUM; DRUG EFFECTS; HUMAN; MICROBIOLOGY; PROCEDURES; REFERENCE VALUE; STANDARDS;

BACTERIA (MICROORGANISMS); ENTEROBACTER CLOACAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIA; BACTERIAL INFECTIONS; DISK DIFFUSION ANTIMICROBIAL TESTS; HUMANS; REFERENCE VALUES;

EID: 84929379016     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03506-14     Document Type: Article

References (58)

1. European Committee on Antimicrobial Susceptibility Testing. 2014. Zone diameter distributions. EUCAST, Växjö, Sweden. http://mic.eucast .org/Eucast2/.
2. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
3. European Committee on Antimicrobial Susceptibility Testing. 2010. Setting breakpoints for new agents. Standard operating procedure 1.1. EUCAST, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/EUCAST-SOPs/EUCAST-SOP-1.-1-Setting-breakpoints-new-agents-1-June-2013.pdf.
4. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20:391-408. http://dx.doi.org/10.1128/CMR.00047-06.
5. Williams JD. 1990. Prospects for standardisation of methods and guidelines for disc susceptibility testing. Eur J Clin Microb Infect Dis 9:496-501. http://dx.doi.org/10.1007/BF01964290.
6. Valsesia G, Hombach M, Maurer FP, Courvalin P, Roos M, Böttger EC. 2015. The resistant-population cutoff (RCOFF): a new concept for improved characterization of antimicrobial susceptibility patterns of nonwild- type bacterial populations. J Clin Microbiol 53:1806-1811. http://dx.doi.org/10.1128/JCM.03505-14.
7. Metzler CM, DeHaan RM. 1974. Susceptibility tests of anaerobic bacteria: Statistical and clinical considerations. J Infect Dis 130:588-594. http://dx.doi.org/10.1093/infdis/130.6.588.
8. Brunden MN, Zurenko GE, Kapik B. 1992. Modification of the errorrate bounded classification scheme for use with two MIC break points. Diagn Microbiol Infect Dis 15:135-140. http://dx.doi.org/10.1016/0732 -8893(92)90037-T.
9. Kronvall G. 2010. Normalized Resistance Interpretation as a tool for establishing epidemiological MIC susceptibility breakpoints. J Clin Microbiol 48:4445-4452. http://dx.doi.org/10.1128/JCM.01101-10.
10. Kronvall G, Kahlmeter G, Myhre E, Galas MF. 2003. A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes. Clin Microbiol Infect 9:120-132. http://dx.doi.org/10.1046/j.1469-0691.2003.00546.x.
11. Craig BA. 2000. Modeling approach to diameter breakpoint determination. Diagn Microbiol Infect Dis 36:193-202. http://dx.doi.org/10.1016/S0732-8893(99)00130-3.
12. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. http://dx.doi.org/10.1111/j.1469-0691.2006.01377.x.
13. Ringertz S, Olsson-Liljequist B, Kahlmeter G, Kronvall G. 1997. Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance. Scand J Infect Dis Suppl 105:8-12.
14. Kronvall G, Giske CG, Kahlmeter G. 2011. Setting interpretive breakpoints for antimicrobial susceptibility testing using disk diffusion. Int J Antimicrob Agents 38:281-290. http://dx.doi.org/10.1016/j.ijantimicag .2011.04.006.
15. Hombach M, Böttger EC, Roos M. 2013. The critical influence of the intermediate category on interpretation errors in revised EUCAST and CLSI antimicrobial susceptibility testing guidelines. Clin Microbiol Infect 19:E59-E71. http://dx.doi.org/10.1111/1469-0691.12090.
16. Kahlmeter G. 2014. Defining antibiotic resistance-towards international harmonization. Ups J Med Sci 119:78-86. http://dx.doi.org/10.3109/03009734.2014.901446.
17. Greiner M, Pfeiffer D, Smith RD. 2000. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 45:23- 41. http://dx.doi.org/10.1016/S0167 -5877(00)00115-X.
18. Zweig MH, Campbell G. 1993. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39: 561-577.
19. Bouza E, Alcalá L, Muñoz P, Martín-Rabadán P, Guembe M, Rodríguez- Créixems M. 2013. Can microbiologists help to assess catheter involvement in candidaemic patients before removal? Clin Microbiol Infect 19:E129-E135. http://dx.doi.org/10.1111/1469-0691.12096.
20. Blackburn J, Tsimiklis C, Lavergne V, Pilotte J, Grenier S, Gilbert A, Lefebvre B, Domingo M-C, Tremblay C, Bourgault AM. 2013. Carbapenem disks on MacConkey agar in screening methods for detection of carbapenem-resistant Gram-negative rods in stools. J Clin Microbiol 51: 331-333. http://dx.doi.org/10.1128/JCM.02878-12.
21. Kaasch AJ, Rieg S, Hellmich M, Kern WV, Seifert H. 2014. Differential time to positivity is not predictive for central line-related Staphylococcus aureus bloodstream infection in routine clinical care. J Infect 68:58-61. http://dx.doi.org/10.1016/j.jinf.2013.08.006.
22. He S, Hang J-P, Zhang L, Wang F, Zhang D-C, Gong F-H. A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: focus on cutoff levels. J Microbiol Immunol Infect, in press. http://dx.doi.org/10.1016/j.jmii.2014.06.009.
23. Hombach M, Courvalin P, Böttger EC. 2014. Validation of antibiotic susceptibility testing guidelines in a routine clinical microbiology laboratory exemplifies general key challenges in setting clinical breakpoints. Antimicrob Agents Chemother 58:3921-3926. http://dx.doi.org/10.1128/AAC.02489-13.
24. Matuschek E, Brown DFJ, Kahlmeter G. 2014. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect 20:O255-O266. http://dx.doi.org/10.1111/1469-0691.12373.
25. European Committee on Antimicrobial Susceptibility Testing. 2014. EUCAST disk diffusion manual 2014, version 4.0. EUCAST, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/Breakpoint-table-v-4.0.pdf.
26. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
27. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M. 2011. Practical approach for reliable detection of AmpC beta-lactamaseproducing Enterobacteriaceae. J Clin Microbiol 49:2798-2803. http://dx.doi.org/10.1128/JCM.00404-11.
28. European Committee on Antimicrobial Susceptibility Testing. 2013. The EUCAST guideline on detection of resistance mechanisms, version 1. EUCAST, Växjö, Sweden. http://www.eucast.org/resistance-mechanisms/.
29. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M. 2012. Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum β-lactamases (ESBL) in Enterobacteriaceae. Clin Microbiol Infect 18:1194-1204. http://dx.doi.org/10.1111/j.1469-0691.2011.03737.x.
30. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Hombach M. 2012. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates. J Antimicrob Chemother 67:159-166. http://dx.doi.org/10.1093/jac/dkr400.
31. Maurer FP, Castelberg C, Quiblier C, Bloemberg GV, Hombach M. 2015. Evaluation of carbapenemase screening and confirmation tests with Enterobacteriaceae and development of a practical diagnostic algorithm. J Clin Microbiol 53:95-104. http://dx.doi.org/10.1128/JCM.01692-14.
32. Maurer FP, Courvalin P, Böttger EC, Hombach M. 2014. Integrating forecast probabilities in antibiograms: A way to guide antimicrobial prescriptions more reliably? J Clin Microbiol 52:3674-3684. http://dx.doi .org/10.1128/JCM.01645-14.
33. Roy C, Segura C, Torrellas A, Reig R, Teruel D, Hermida M. 1989. Activity of amoxicillin/clavulanate against β-lactamase-producing Escherichia coli and Klebsiella spp. J Antimicrob Chemother 24(suppl):41-47. http://dx.doi.org/10.1093/jac/24.suppl-B.41.
34. Leclercq R, Cantón R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G. 2013. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141-160. http://dx.doi.org/10.1111/j.1469-0691.2011.03703.x.
35. Altman DG. 1991. Practical statistics for medical research. Chapman & Hall, London, United Kingdom.
36. Kirkwood BR, Sterne JAC. 2003. Essentials of medical statistics, 2nd ed. Blackwell Science, Malden, MA.
37. Swets JA. 1988. Measuring the accuracy of diagnostic systems. Science 240:1285-1293. http://dx.doi.org/10.1126/science.3287615.
38. Bauer AW, Kirby WM, Sherris JC, Turck M. 1966. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 45: 493-496.
39. Kahlmeter G, Brown DFJ. 2004. Harmonization of antimicrobial breakpoint in Europe-can it be achieved? Clin Microbiol Newsl 26:187-192. http://dx.doi.org/10.1016/S0196-4399(04)80015-1.
40. Kahlmeter G, Brown DFJ, Goldstein FW, MacGowan AP, Mouton JW, Österlund A, Rodloff A, Steinbakk M, Urbaskova P, Vatopoulos A. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 52:145-148. http://dx.doi.org/10.1093/jac/dkg312.
41. Paterson DL, Ko W-C, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206-2212. http://dx.doi.org/10.1128/JCM.39.6.2206-2212.2001.
42. Pai H, Kang C-I, Byeon J-H, Lee K-D, Park WB, Kim H-B, Kim E-C, Oh M-d, Choe K-W. 2004. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-β-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 48:3720-3728. http://dx.doi.org/10.1128/AAC.48.10.3720-3728.2004.
43. Yang K, Guglielmo BJ. 2007. Diagnosis and treatment of extendedspectrum and AmpC β-lactamase-producing organisms. Ann Pharmacother 41:1427-1435. http://dx.doi.org/10.1345/aph.1K213.
44. Paterson DL. 2000. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 6:460-463. http://dx.doi.org/10.1046/j .1469-0691.2000.00107.x.
45. Paterson DL, Rossi F, Baquero F, Hsueh P-R, Woods GL, Satishchandran V, Snyder TA, Harvey CM, Teppler H, DiNubile MJ, Chow JW. 2005. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 55:965-973. http://dx.doi.org/10.1093/jac/dki117.
46. Pitout JDD, Laupland KB. 2008. Extended-spectrum β-lactamaseproducing Enterobacteriaceae: An emerging public-health concern. Lancet Infect Dis 8:159-166. http://dx.doi.org/10.1016/S1473-3099(08)70041-0.
47. Ho P-L, Chan W-M, Wong SSY, Young K, Tsang KWT. 2002. Bacteremia caused by Escherichia coli producing extended-spectrum betalactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 34:567-573. http://dx.doi.org/10.1080/00365540210147516.
48. Paterson DL, Bonomo RA. 2005. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 18:657-686. http://dx.doi.org/10.1128/CMR.18.4.657-686.2005.
49. Zimhony O, Chmelnitsky I, Bardenstein R, Goland S, Hammer Muntz O, Navon Venezia S, Carmeli Y. 2006. Endocarditis caused by extendedspectrum- β-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 50:3179-3182. http://dx.doi.org/10.1128/AAC.00218-06.
50. Livermore DM, Andrews JM, Hawkey PM, Ho P-L, Keness Y, Doi Y, Paterson D, Woodford N. 2012. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 67:1569-1577. http://dx.doi.org/10.1093/jac/dks088.
51. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á, Extended- Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. 2012. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:167-174. http://dx.doi.org/10.1093/cid/cir790.
52. Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez- Herrera J, Rodríguez-Baño J, Pascual A, Pachón J. 2013. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother 57:2109-2113. http://dx.doi .org/10.1128/AAC.02190-12.
53. European Committee on Antimicrobial Susceptibility Testing. 2014. Antibiotic/organism combinations lacking clinical data. EUCAST, Växjö, Sweden. http://www.eucast.org/clinical-breakpoints/antibiotics-lacking-clinical-data/.
54. Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM. 2008. Prevalence and spread of extended-spectrum β-lactamase- producing Enterobacteriaceae in Europe. Clin Microbiol Infect 14: 144-153. http://dx.doi.org/10.1111/j.1469-0691.2007.01850.x.
55. Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PRS, Adam HJ, Hoban DJ. 2011. Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamaseproducing Escherichia coli: Results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 69:326-334. http://dx.doi.org/10.1016/j.diagmicrobio.2010.10.029.
56. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. 2013. Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: Report from the SENTRY antimicrobial surveillance program (2010). Antimicrob Agents Chemother 57:3012-3020. http://dx.doi.org/10.1128/AAC.02252-12.
57. Sheng W-H, Badal RE, Hsueh P-R. 2013. Distribution of extendedspectrum β-lactamases,AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia- Pacific region: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 57:2981-2988. http://dx.doi.org/10.1128/AAC.00971-12.
58. Miró E, Aguïero J, Larrosa MN, Fernández A, Conejo MC, Bou G, González-López JJ, Lara N, Martínez-Martínez L, Oliver A, Aracil B, Oteo J, Pascual A, Rodríguez-Baño J, Zamorano L, Navarro F. 2013. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 32:253-259. http://dx.doi.org/10.1007/s10096-012-1737-0.